Breaking News: Innocan Pharma - the superstar at "PAINWEEK"?

Advertisement / Advertising

Once a year, leading pain specialists from around the world meet at the "PAINWEEK" conference to exchange ideas, learn, and explore the latest advances in pain management.

Liposomal synthetic CBD could provide a safe and scalable solution for a variety of pain conditions.

Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine.

- Please be sure to read the complete ad hoc announcements and filings with the authorities, as well as the existing conflicts of interest and the disclaimer further down in the text. - Advertorial/Advertising (Client: InnoCan Pharma* (WKN: A2PSPW )) -

LPT-CBD from InnoCan Pharma* (WKN: A2PSPW ) is an innovative injectable liposomal drug product developed for the sustained release of synthetic CBD. Various animal studies demonstrate that LPT-CBD produces stable plasma CBD levels for up to four weeks, provides sustained pain relief, and is well tolerated. This makes it a promising alternative to conventional opioid medications and opioid abuse. InnoCan Pharma* (WKN: A2PSPW ) has entered into an agreement with the FDA regarding its preclinical and clinical plans to advance LPT-CBD for human clinical trials.

As part of InnoCan Pharma*'s (WKN: A2PSPW ) PAINWEEK presentation, the company will present its LPT-CBD technology to thousands of experts, which is expected to cause a stir in the scientific community.

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

InnoCan Pharma* (WKN: A2PSPW ) announces that the recently published narrative report entitled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: https://doi.org/10.7759/cureus.81577 ) has been officially accepted for presentation at PAINWEEK 2025, the national conference for pain management taking place in September in Las Vegas, Nevada.

PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in pain medicine, providing a unique platform to showcase innovative research and best practices. Selected through a competitive peer-review process, this narrative review provides important insights into the potential of synthetic cannabidiol (CBD) in sustained-release formulations as a well-tolerated, opioid-free pain relief alternative.

LPT-CBD will be presented to thousands of healthcare professionals and potential pharmaceutical partners at the PAINWEEK conference, positioning LPT-CBD as a pioneer in groundbreaking non-opioid solutions for the treatment of chronic pain.

We are pleased to present our technology to thousands of experts and specialists in the field of pain management. This recognition underscores our commitment to advancing evidence-based pain management and our contribution to significant research in this field.

Iris Bincovich, Chief Executive Officer of InnoCan Pharma* (WKN: A2PSPW )

News conclusion:

Painkillers can be broadly divided into non-opioid and opioid analgesics. Non-opioid painkillers include paracetamol, ibuprofen, naproxen, and aspirin (ASA), which are often used for mild to moderate pain. Opioids such as codeine, tramadol, fentanyl, or morphine are used for severe or moderate pain that does not respond well to non-opioid treatment.

And now comes LPT-CBD from InnoCan Pharma* (WKN: A2PSPW ) . A completely new delivery technology for an ancient molecule. While the pain-relieving effects of CBD are well-documented, its therapeutic potential has been limited by its rapid degradation in the body, typically within a few hours. InnoCan Pharma* (WKN: A2PSPW ) has solved this problem by encasing CBD in liposomes, releasing it into the blood over a period of weeks. Numerous animal studies on dogs, goats, and donkeys have proven its effectiveness – pain-stricken, immobile animals have regained mobility!

We consider this news a breakthrough for InnoCan Pharma* (WKN: A2PSPW ) . The company is now stepping out of the shadows and into the spotlight of pain specialists worldwide! Likewise, the stock should now also become visible to biotech investors!

Opinion Editorial

Given the current addiction crisis, there is an urgent need to replace opioids with safer and more effective alternatives," he noted. Long-acting synthetic CBD has the potential to bring about a true paradigm shift.

Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health

Steep sales curve

INNOCAN PHARMA CORP.* WKN: A2PSPW CSE: INNO

Tip: Want to boost your portfolio with this stock? Discover SMARTBROKER+ now!

The public has already learned from the results of preclinical animal studies that InnoCan Pharma*'s (WKN: A2PSPW ) LPT therapy (a monthly subcutaneous injection) is a highly effective medication for arthritic pain. The condition of donkeys, goats, and dogs that had become immobile improved dramatically due to its anti-inflammatory effect. The drug is already on the FDA approval path!

Superior to the competition

The drug, developed by InnoCan Pharma* (WKN: A2PSPW ) , only needs to be administered once a month—that's a win-win! But there's more:

Treatment example:

Despite painkillers, the donkey Miri found no relief and was unable to move, so her keepers recommended euthanasia. In an act of compassion, the donkey was given a liposome CBD injection. The effect was immediate, and Miri became active again, roaming the farm. After the liposome CBD injection, Miri was able to walk and move as she had before her laminitis.

LPT therapy works. In the past, numerous dogs and goats have regained mobility through its almost miraculous effects. But we consider this donkey example even more significant, as it proves that LPT therapy restores mobility.

Long-term effect without compromises:

In two ongoing cases, dogs suffering from osteoarthritis treated with LPT-CBD after failing to respond to nonsteroidal anti-inflammatory drugs (NSAIDs) and oral CBD showed noticeable pain relief, significantly improved mobility, and a significantly increased sense of well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively, after their owners reported a significant improvement in their quality of life.

Why it can work

The anti-inflammatory effect of CBD is well known, but the body typically excretes it within a few hours, preventing it from fully developing its effects. LPT-CBD injections can maintain a constant level of CBD in the body—this appears to be responsible for its sensational effect in combating arthritis pain and other applications.

CONCLUSION:

We think it's not difficult to recognize the enormous potential of InnoCan Pharma* (WKN: A2PSPW) . An investment could yield returns beyond the reach of the general public.

Note - Disclaimer

This communication is a marketing communication.

This communication has been prepared solely for information purposes and does not constitute a recommendation, financial analysis, or investment advice within the meaning of the Securities Trading Act (WpHG) in Germany or the Securities Supervision Act 2018 (WAG 2018) in Austria. It is intended for general information purposes and is aimed at experienced and risk-conscious investors.

The information contained herein is based on sources considered reliable by bullvestor Medien GmbH; however, no guarantee can be given for their accuracy, completeness, or timeliness. The assessments contained in this publication represent the subjective opinion of the authors and are subject to change at any time without prior notice. Historical performance or forecasts are not a reliable indicator of future results, and such statements may involve significant uncertainties and risks, which is why actual results could differ materially from the scenarios described.

Investors should carefully consider their financial situation and risk tolerance before making any investment and, if necessary, seek independent advice, but should not base their investment decision on this communication.

The following disclosure is provided solely for prudential reasons and to comply with legal requirements in the event that this communication should nevertheless be construed as an investment recommendation, contrary to the express notice above:

1. Identity of the distributor according to Art. 20 MAR in conjunction with Art. 2 of Regulation (EU) 2016/958

This press release was prepared by Helmut Pollinger for bullvestor Medien GmbH and published by them.

1. Disclosure of conflicts of interest pursuant to Art. 20 MAR in conjunction with Art. 5 of Regulation (EU) 2016/958

bullvestor Medien GmbH acts on behalf of InnoCan Pharma* (WKN: A2PSPW ) and received compensation from InnoCan Pharma* (WKN: A2PSPW ) for the preparation and distribution of this press release. Furthermore, bullvestor Medien GmbH and InnoCan Pharma* (WKN: A2PSPW ) maintain an ongoing business relationship.

The publication of this announcement is intended to increase market activity for the share of InnoCan Pharma* (WKN: A2PSPW ) , which brings economic benefits to the client of the publication and related parties.

Due to these circumstances, bullvestor Medien GmbH is subject to conflicts of interest, which is why the objectivity of the published communication cannot be guaranteed. Investors should consider the described conflicts of interest and the resulting risk of influencing the objectivity of the information contained in this communication when making their investment decision.

Media owner & publisher: bullVestor Medien GmbH, 4300 Sankt Valentin, Gutenhofen 4

Phone: +43 7435 540 77

Commercial register number: FN 275279yUID number: ATU 62435644

LEI: 549300IB9WNO0P0OFS60

Managing Director/Sole Shareholder: Helmut Pollinger

Responsible for the content according to § 55 para. 2 RStV: Helmut Pollinger

Disclaimer

We expressly point out that we assume no liability for the content of external links.

Any investment in securities involves risks. Political, economic, or other changes can lead to significant price losses. This is particularly true for investments in (foreign) small-cap stocks and small- and micro-cap companies. Due to their low market capitalization, investments in such securities are highly speculative and carry a high risk, including the total loss of the invested capital. Furthermore, some of the stocks presented on bullVestor are subject to currency risks.

All information and analyses do not constitute a solicitation, offer, or recommendation to purchase or sell investment instruments or for any other transactions. Any investment in stocks, bonds, options, or other financial products involves risks—some of which are substantial. The publisher and authors of bullVestor publications are not professional investment advisors; therefore, please always seek advice from a qualified professional (e.g., your bank or a qualified advisor you trust) when making investment decisions.

All information and data published by bullvestor originate from sources we consider reliable and trustworthy at the time of preparation. However, no guarantee can be given regarding the accuracy and completeness of this information and data. The same applies to the evaluations and statements contained in the analyses and market assessments of inult/bullvestor; these were prepared with due care. We assume no responsibility or liability for the accuracy and completeness of the information contained in this publication.

All opinions expressed reflect the current assessment of the authors, which is subject to change at any time without prior notice. Bullvestor expressly assumes no guarantee or liability that the price or earnings developments forecast in its publications will occur.

Included values: CA45783P1027